Supplementary material to article by J. M. Sobell et al. “Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis”

Fig. S1. Design of the ESTEEM 1 and 2 studies. *Doses of apremilast were titrated during the first week of administration and at Week 16 when placebo patients were switched to apremilast. †PASI-75 (ESTEEM 1) or PASI-50 (ESTEEM 2). §In ESTEEM 1, patients were switched to apremilast at the time of loss of PASI-75, but no later than Week 52. In ESTEEM 2, patients were switched to apremilast at time of loss of effect, defined as time of loss of 50% of the PASI improvement obtained at Week 32 compared to baseline, but no later than Week 52. Patients initially on placebo or randomized to apremilast 30 mg BID who did not attain a PASI-75 (ESTEEM 1) or PASI-50 (ESTEEM 2) were able to add topicals and/or UVB at Week 32 at the discretion of the investigator.